Intracellular Membrane Attack Complexes and COVID-19 Immune Hyperactivation
细胞内膜攻击复合体和 COVID-19 免疫过度激活
基本信息
- 批准号:10725199
- 负责人:
- 金额:$ 25.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-05-19 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVAlveolarAntigensBindingBinding ProteinsBiological AssayBlood capillariesCOVID-19COVID-19 patientCell DeathCell surfaceCellsClinicalComplementComplement ActivationComplement Membrane Attack ComplexComplexComplicationCytolysisDataDepositionDiabetes MellitusEdemaEndosomesEndothelial CellsFamilyFunctional disorderGBP1 geneHomeostasisHost DefenseHumanHypertensionImmuneImmunityIn VitroInfectionInflammationInflammation MediatorsInflammatoryIntracellular MembranesLifeLungMediatingMembraneMolecularMusNatural ImmunityOrthologous GeneOutcomePatient-Focused OutcomesPatientsPhenotypeProcessPropertyProtein IsoformsProteinsProteomicsRoleSARS-CoV-2 antigenSARS-CoV-2 infectionSARS-CoV-2 spike proteinSequence HomologySignal TransductionSurfaceSymptomsTestingTissuescell typecytokinecytokine release syndromedruggable targetguanylateimprovedin vivolung injurymembrane assemblyneoantigensnovelprotein aggregationprotein complexresponsesensorsevere COVID-19soluble complement C5b-9stemtissue injuryvascular inflammationvirtual
项目摘要
PROJECT SUMMARY
During severe COVID-19, immune hyperactivation contributes to tissue injury and worsened patient
outcomes. Complement (C’) proteins are believed to centrally mediate COVID-19-related immune
hyperactivation. C’ are a conserved set of immune proteins involved in host defense that become activated on
various cell types in the lung during severe COVID-19. Upon terminal activation, C’ proteins assemble to form
pore-like membrane attack complexes (MACs) that insert into target cell surfaces as transmembrane
structures. The presence of MACs in pulmonary tissues strongly correlates with immune hyperactivation, but
underlying mechanisms are unknown.
The immune effects of MACs have been widely attributed to their cytolytic properties. However,
widespread MAC deposition occurs on alveolar endothelial cells (ECs) during severe COVID-19 in the absence
of significant EC death or vessel rarefaction. Instead, MAC-bound ECs show signs of EC dysfunction with
dysregulated NF-B activation and elaboration of pro-inflammatory cytokines. These patient-level observations
suggest immune effects of MACs that are separable from their cytolytic properties.
In this application we examine a novel role for intracellular MAC proteins as alarmins. We used a
SARS-CoV-2-derived antigen, S protein, to induce non-cytolytic MAC assembly on human ECs. Following
assembly on ECs, surface-bound MACs became rapidly internalized and transferred to Rab5+ endosomes.
The pool of intracellular, but not extracellular or surface-bound MACs, activated NF-B to induce elaboration of
inflammatory cytokines. The intraluminal milieu of Rab5+ endosomes caused a MAC protein, C9, to form
insoluble aggregates that stimulated aggrephagy, a specialized form of selective macroautophagy, to activate
NF-B. Via proteomic profiling of solubilized MAC complexes (Sc5b-9) in COVID-19 sera, we identified
guanylate binding protein 4 (GBP4) as a C9-binding protein regulating aggrephagy and NF-B activity.
Based on these exciting preliminary data we propose 2 Specific Aims to explore the hypothesis that
intracellular MAC proteins act as alarmins to initiate inflammatory signaling. We will consolidate role(s) for
GBP4 as an immune sensor by examining binding interactions with C9 using COVID-19 patient sera.
Secondly, we will identify mouse orthologs for human GBP4 that mediate C9 sensing and MAC-induced
immune hyperactivation in vivo in response to S protein-induced MAC and following infection by replication
competent SARS-CoV-2. Our studies introduce a new paradigm for understanding MAC-related immunity and
contribute to our long-term aim of understanding C’-induced inflammation. By doing this, druggable targets
ameliorating MAC-induced immune complications of severe COVID-19 may emerge.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DANIEL JANE-WIT其他文献
DANIEL JANE-WIT的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DANIEL JANE-WIT', 18)}}的其他基金
Hedgehog-Induced Activation of Alloimmune T Cells During Ischemia Reperfusion Injury
Hedgehog 诱导缺血再灌注损伤期间同种免疫 T 细胞的激活
- 批准号:
10514589 - 财政年份:2020
- 资助金额:
$ 25.13万 - 项目类别:
Hedgehog-Induced Activation of Alloimmune T Cells During Ischemia Reperfusion Injury
Hedgehog 诱导缺血再灌注损伤期间同种免疫 T 细胞的激活
- 批准号:
10015395 - 财政年份:2020
- 资助金额:
$ 25.13万 - 项目类别:
Hedgehog-Induced Activation of Alloimmune T Cells During Ischemia Reperfusion Injury
Hedgehog 诱导缺血再灌注损伤期间同种免疫 T 细胞的激活
- 批准号:
10293588 - 财政年份:2020
- 资助金额:
$ 25.13万 - 项目类别:
Complement-Induced Endothelial Cell Activation by a Novel Rab5-ZFYVE21-SMURF2 Signaling Axis
新型 Rab5-ZFYVE21-SMURF2 信号轴补体诱导内皮细胞激活
- 批准号:
10294356 - 财政年份:2018
- 资助金额:
$ 25.13万 - 项目类别:
Complement-Induced Endothelial Cell Activation by a Novel Rab5-ZFYVE21-SMURF2 Signaling Axis
新型 Rab5-ZFYVE21-SMURF2 信号轴补体诱导内皮细胞激活
- 批准号:
9912195 - 财政年份:2018
- 资助金额:
$ 25.13万 - 项目类别:
Complement-Induced Endothelial Cell Activation by a Novel Rab5-ZFYVE21-SMURF2 Signaling Axis
新型 Rab5-ZFYVE21-SMURF2 信号轴补体诱导内皮细胞激活
- 批准号:
10374856 - 财政年份:2018
- 资助金额:
$ 25.13万 - 项目类别:
THE ROLE OF ZFYVE21 IN CEREBRAL AMYLOID ANGIOPATHY IN ALZHEIMER'S DISEASE
ZFYVE21 在阿尔茨海默病脑淀粉样血管病中的作用
- 批准号:
10288327 - 财政年份:2018
- 资助金额:
$ 25.13万 - 项目类别:
Mechanisms of Non-Canonical NF-kB Activation in Transplant Arteriosclerosis
移植动脉硬化中非典型 NF-kB 激活机制
- 批准号:
9376977 - 财政年份:2016
- 资助金额:
$ 25.13万 - 项目类别:
Mechanisms of Non-Canonical NF-kB Activation in Transplant Arteriosclerosis
移植动脉硬化中非典型 NF-kB 激活机制
- 批准号:
8805540 - 财政年份:2015
- 资助金额:
$ 25.13万 - 项目类别:
相似海外基金
Gain-of-function toxicity in alpha-1 antitrypsin deficient type 2 alveolar epithelial cells
α-1 抗胰蛋白酶缺陷型 2 型肺泡上皮细胞的功能获得毒性
- 批准号:
10751760 - 财政年份:2024
- 资助金额:
$ 25.13万 - 项目类别:
The role of alveolar macrophages and regulatory pathways in post-transplant lung inflammation.
肺泡巨噬细胞和调节途径在移植后肺部炎症中的作用。
- 批准号:
23K08315 - 财政年份:2023
- 资助金额:
$ 25.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanical signaling through the nuclear membrane in lung alveolar health
通过核膜的机械信号传导影响肺泡健康
- 批准号:
10677169 - 财政年份:2023
- 资助金额:
$ 25.13万 - 项目类别:
Mechanistic studies of the genetic contribution of desmoplakin to pulmonary fibrosis in alveolar type 2 cells
桥粒斑蛋白对肺泡2型细胞肺纤维化的遗传贡献机制研究
- 批准号:
10736228 - 财政年份:2023
- 资助金额:
$ 25.13万 - 项目类别:
Pilot Studies of PAX3-FOXO1 Fusions Proteins in Alveolar Rhabdomyosarcoma
PAX3-FOXO1 融合蛋白在肺泡横纹肌肉瘤中的初步研究
- 批准号:
10726763 - 财政年份:2023
- 资助金额:
$ 25.13万 - 项目类别:
Novel alveolar mechanisms of hypoxemia in hepatopulmonary syndrome
肝肺综合征低氧血症的新肺泡机制
- 批准号:
10718446 - 财政年份:2023
- 资助金额:
$ 25.13万 - 项目类别:
Utilizing induced pluripotent stem cells to study the role of alveolar type 2 cell dysfunction in pulmonary fibrosis
利用诱导多能干细胞研究肺泡2型细胞功能障碍在肺纤维化中的作用
- 批准号:
10591174 - 财政年份:2023
- 资助金额:
$ 25.13万 - 项目类别:
Injury of blood brain and alveolar-endothelial barriers caused by alcohol and electronic cigarettes via purinergic receptor signaling
酒精和电子烟通过嘌呤受体信号传导引起血脑和肺泡内皮屏障损伤
- 批准号:
10638221 - 财政年份:2023
- 资助金额:
$ 25.13万 - 项目类别:
Alveolar Epithelial Cell Dysfunction Induced By Flavored E-Cigarette Aerosols
加味电子烟气雾剂引起的肺泡上皮细胞功能障碍
- 批准号:
10770080 - 财政年份:2023
- 资助金额:
$ 25.13万 - 项目类别:
Delineating the role of let-7 microRNA on lung AT2 cell homeostasis, alveolar regeneration, and interstitial lung disease
描述let-7 microRNA对肺AT2细胞稳态、肺泡再生和间质性肺疾病的作用
- 批准号:
10634881 - 财政年份:2023
- 资助金额:
$ 25.13万 - 项目类别:














{{item.name}}会员




